Skip to main content


Cardiovascular & Metabolism

Cardiovascular & Metabolism

Cardiovascular & Metabolism

Our focus - Cardiovascular & Metabolism

Heart disease, diabetes and chronic kidney disease do not have to be life-threatening. At Janssen, we’re committed to finding innovative new treatments and therapies to help reduce the life-impact of these diseases for the millions of sufferers around the world. We’re here to help you regain a sense of hope for the future.

Our Commitment to Patients


Cardiovascular and metabolic diseases are a major threat to life for adults, accounting for millions of deaths worldwide each year. We want to develop innovative healthcare solutions that will significantly improve the outcome for patients.

  • Heart disease is the number one killer in both men and women worldwide.[1]

  • Diabetes is the seventh leading cause of death in the world.[1]

  • Retinal diseases threaten the eyesight of millions worldwide.[2]

Together we can reshape the future of cardiovascular, metabolic and retinal diseases

As part of our long-standing commitment, and propelled by our successes in treating type 2 diabetes and thrombosis, we are advancing different therapies that prevent and treat life-threatening cardiovascular, metabolic and retinal diseases.

These diseases are growing, straining patients, their families and healthcare systems. Uncovering new therapies that can improve the quality of life for such a large segment of the population is an important endeavour – one which Janssen CVM will continue to lead in the years to come. Our relentless pursuit of innovation across all stages of drug development means patients get the treatments they need, as fast as possible.[3]

Our mission is global, local and personal: to reshape the future of cardiovascular, metabolic and retinal disease prevention and treatment.

Cardiovascular Disease


Cardiovascular diseases are the number one cause of death worldwide, leading to an estimated 31% of all deaths.[4] We can help change this.

  • Life-threatening blood clots, if untreated, can lead to deep vein thrombosis (DVT) or pulmonary embolism (PE) – conditions that affect nearly 10 million people around the world each year.[3]

  • People who have DVT or PE are at higher risk of experiencing other major cardiovascular events, such as heart attack, stroke and myocardial infarction, among others. Although very effective, currently available treatments of thromboembolism are often associated with substantive bleeding risks.[3]

  • We're expanding our understanding of ways in which patients can benefit from established oral anticoagulants (blood thinners), while exploring new ways to treat and prevent thrombosis. We’re focusing on next-generation anticoagulant assets, which are safer and equally as effective.[3]

Metabolic disease


We’re using our established and pipeline medicines to treat and prevent life‑threatening conditions that significantly impact overall health, beginning with chronic kidney disease and obesity.

Chronic Kidney Disease

  • Nearly half of all people with type 2 diabetes have chronic kidney disease, which is associated with an increased risk of kidney failure and cardiovascular disease.[5]

  • With current care, treatment for end-stage kidney disease is limited to dialysis and kidney transplants, which are both costly and associated with short life expectancy. Despite this immense medical need, it has been two decades since a new treatment for diabetic kidney disease has been identified.[4]

  • Our goal is to change that in the near future. By exploring additional renal benefits of our established sodium-glucose cotransporter 2 (SGLT2) inhibitor, as well as several promising early pipeline drugs, we are moving closer each day to bringing new treatments to people living with chronic kidney disease.[4]


Nearly 13% of adults worldwide are obese. Obesity can lead to increased rates of cardiovascular disease, diabetes, non-alcoholic fatty liver disease and other life-threatening complications. That is why we are focused on finding effective weight-reducing therapies for obese patients at the highest risk of disease.[4]

Retinal Disease


We are translating our understanding of the biology behind retinal diseases into developing much‑needed therapies.

  • Today, people suffering from diabetic retinopathy, diabetic macular edema and wet age-related macular degeneration have very limited treatment options. With the currently available therapies, which use an anti-VEGF mechanism, a large proportion of patients still end up with significant visual impairment, and administration of these treatments proves challenging for many.[6]

  • We want to uncover the pathology of these conditions, identify targets for therapy and bring treatments to people in need, which improve visual ability and prevent the complete loss of vision. To do this, we are using our existing expertise in immunology, vascular disease and neuroscience, and collaborating with leading research communities to explore the underlying biology of retinal diseases.

Cardiovascular & Metabolism in numbers


Over a period of 70 years, a human heart will beat more than 2.5 billion times.[7]


Each year cardiovascular disease (CVD) causes over 4 million deaths in Europe.[8]


CVD is estimated to cost the EU economy €210 billion a year.[9]


Nearly 55 million people (aged 20-79) in the Middle East and Africa have diabetes.[10]


The health expenditure allocated to treat diabetes and prevent complications is estimated at about €136 billion in Europe.[9]


We’re Focused on Disease Areas with High Unmet Need

Within Cardiovascular & Metabolism, we are concentrating on finding the next generation of treatments, and we strive to find and apply the best science for transforming and eliminating these diseases by starting with truly understanding the underlying mechanisms of the diseases.

We believe that early drug development – exploring new compounds, studying them in depth, and critically evaluating their promise as therapeutic agents – can achieve its full potential when scientific promise is matched with world-class development and commercialisation.


Working Together to Make a Difference

We work across our company to deliver new therapies from laboratory to patient. Our research and development strengths, in addition to our infrastructure, means our development process is seamless.

We know that no one company, no single academic institution, can solve the challenge of these diseases alone. We look for the best science and best scientific minds in industry and academia – whether they are inside or outside our company – to confront the challenge.

Fully Integrated end-to-end development

Once we determine that a compound has the potential to provide real clinical benefit, we dedicate our fully aligned resources to move forward with development.

We harness our in-depth understanding of the disease and the target's biology, and factor in the needs of clinicians and their patients. We then conduct clinical trials that evaluate and validate the compound and meet the needs of our medical and regulatory stakeholders.

We operate with an intensity that characterises the best of biotech, backed by the resources of a global healthcare company.

We use our broad development experience and flexible organisation to bring development strategies together for novel treatments and platforms, and have dedicated teams that help successfully navigate the global regulatory environment.



We engage in diverse and varied partnerships at all levels of the discovery and development process through our regional Innovation Centers and our Business Development group.

These teams of scientific, transaction and alliance management experts lead the identification, evaluation and execution of agreements relating to compounds (early-stage discovery programmes through to marketed products) and technologies.

Together, our Innovation Centers and Business Development teams drive the strategic focus and manage our external collaborations for mutual long-term success with academic institutions, venture investors and biotech and large pharmaceutical companies alike.

In several European countries, Janssen is partnering with Mundipharma on diabetes products.

Learn more about collaborating with us



[1] World Health Organisation. The top 10 causes of death. Available: Accessed: December 2020.

[2] Wan Ling Wong, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. 2014 The Lancet Global Health; 2(2):e106-e116.

[3] Janssen. Cardiovascular & Metabolism. Available: Accessed: December 2020.

[4] Janssen. Cardiovascular Disease. Available: Accessed: December 2020.

[5] Janssen. Metabolic Disease. Available: Accessed: December 2020..

[6] Janssen. Retinal Disease. Available: Accessed: December 2020.

[7] American Heart Association. About Arrhythmia. Available: Accessed: December 2020.

[8] Townsend N, et al. Cardiovascular disease in Europe: epidemiological update 2016. European Society of Cardiology. 2016: 37, 3232-3245.

[9] European Heart Network. European Cardiovascular Disease Statistics 2017. Available: Accessed: December 2020

[10] International Diabetes Federation. IDF Diabetes Atlas Ninth edition 2019. Available at: Access December 2020.